Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Morgan Stanley Wealth Management CIO: U.S. stocks to rise further in H2

Morgan Stanley Wealth Management CIO: U.S. stocks to rise further in H2

Bitget2024/06/06 22:45

The U.S. stock market will continue its upward trend in the second half of 2024, albeit at a faster pace, said Lisa Shallett, CIO of Morgan Stanley Wealth Management. “Between now and the end of the year, the resistance is the market moving higher.” Nevertheless, investors should have “modest expectations” for stock prices between now and December, Shallett added, adding that the SP 500 has risen 12 percent so far this year. Despite her optimism, Sharlet said the expansion in corporate profits this year has already been reflected in stock prices, and investors will need to start “borrowing” from expectations for 2025 as 2024 continues to unfold. On the bright side, she expects gains to expand into sectors where the market has been stagnant, despite the mega-cap tech giants that have driven much of the rally since last year.

2
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).

智通财经2026/09/21 07:11

Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential

According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.

智通财经2026/09/21 07:11

Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.

TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).

智通财经2026/09/21 07:11